JavaScript seems to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.

Welcome visitor, you can

For all locations except UK and Europe please use US Dollars

Default welcome msg!

Home
About

Company Profile

Badrilla Ltd, founded in 2003, is an established life science company providing high quality products for the molecular cardiovascular researcher located within major pharmaceutical, biotech, and academic establishments worldwide... Read More

Management Team

Professor Colyer established Badrilla in 2003, combining substantive entrepeneurial experience with a deep understanding of the cardiovascular research field. The company has grown organically, reinvesting revenues into... Read More
Products
Technology
The Blog
Contact

Home
Products
Research Themes
The UPS and Heart Failure

Back

The UPS and Heart Failure

Increased levels of ubiquitinated proteins are observed in failing hearts

A functional ubiquitin-proteasome system (UPS) is critical for normal protein turnover and its role is to remove damaged or misfolded proteins via proteolysis of polyubiquitinated species. The accumulation of polyubiquitinated proteins is a hallmark of proteasome dysfunction and is the most commonly used measure for assessing UPS function in human DCM and heart failure. A consistent observation is that levels of polyubiquitinated proteins are increased in DCM/failing hearts compared with control hearts (find out more about this here). This is typically measured by semi-quantitative Western blot analysis using ubiquitin antibodies.

Key findings to date:

Evidence mounting to link proteasome dysfunction with a variety of cardiac diseases
There is significant complexity in the regulation of the UPS in the heart
A consistent observation that levels of polyubiquitinated proteins are increased in DCM/failing hearts
There is substantial interest in developing novel therapeutics that target ubiquitin conjugation and the UPS

Further reading: The ubiquitin proteasome system in human cardiomyopathies and heart failure. Am J Physiol Heart Circ Physiol. 2013 May 15; 304(10): H1283–H1293. [PubMed]

Which tools do I need? Badrilla is pleased to offer new panel of reagents to facilitate the study of the ubiquitin-proteasome system in cardiac samples.

Epoxomicin

$257.00

Product code: A010-512

Proteasome-specific and highly potent, cell permeable, irreversible inhibitor. Reacts with all three active sites of the proteasome, primarily targets chymotrypsin-like activity.
Learn More
MG132

$136.00

Product code: A010-511

Key reversible, cell-permeable proteasome inhibitor - chymotrypsin-like and caspase-like activity. Calpain / cathepsin inhibitor. Autophagy activator.
Learn More